Effect of angiotensin converting enzyme inhibitors on periprocedural myocardial infarction in patients with metabolic syndrome

Creative Commons License

Ozcan O. U., Ustun E. E., GÜLEÇ H. S., GEREDE ULUDAĞ D. M., Goksuluk H., Vurgun V. K., ...Daha Fazla

CARDIOLOGY JOURNAL, cilt.22, sa.3, ss.323-329, 2015 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 3
  • Basım Tarihi: 2015
  • Doi Numarası: 10.5603/cj.a2014.0101
  • Dergi Adı: CARDIOLOGY JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.323-329
  • Anahtar Kelimeler: angiotensin converting enzyme inhibitor, coronary artery disease, metabolic syndrome, percutaneous coronary intervention, periprocedural myocardial infarction, CREATINE KINASE-MB, INTRACORONARY ENALAPRILAT, CARDIOVASCULAR EVENTS, MORTALITY, DISEASE, IMPACT, TRIAL
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: Metabolic syndrome (MetS) has been reported as a risk factor for cardiovascular events. The aim of the present study is to investigate the association between chronic angiotensin-converting enzyme inhibitors (ACE-I) therapy and the rate of periprocedural myocardial infarction (PMI) after elective coronary stenting among patients with MetS.